VLIYaNIE KOMBINATsII METFORMINA I VILDAGLIPTINA NA POKAZATELI UGLEVODNOGO I ZhIROVOGO OBMENOV U BOL'NYKh SAKhARNYM DIABETOM 2 TIPA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of evaluation of the effect of combination therapy on body weight and fat distribution in 70 patients with type 2 diabetes mellitus (DM2) with abdominal obesity, using magnetic resonance imaging to visualize the visceral adipose tissue. The main group consisted of 40 patients, for whom therapy with metformin to compensate for carbohydrate metabolism was added by drug vildagliptin 100 mg/day. The comparison group included 30 patients, for whom treatment with metformin was added by drug glibenclamide at a dose of 3.5 to 7.5 mg/day. It has been shown that combination therapy with metformin and vildagliptin (Galvus Met) is optimal because it synergistically enhances the therapeutic effects, affects all major pathogenetic mechanisms of DM2 with minimal risk of side effects, and promotes slowing of progression of DM2.

Full Text

Restricted Access

References

  1. Аметов А.С. Избранные лекции по эндокринологии. М., 2009; 496 с.
  2. Анциферов М.Б., Зилов А.В. Перспективы применения ингибиторов ДПП-4 при сахарном диабете 2: инициация и продолжение терапии. Фарматека. 2010; 16: 10-4.
  3. Балаболкин М.И., Клебанова Е.М., Креминская В.М. Функциональная активность Р-клеток, состояние инсулиновой резистентности, секреция лептина и α-фактора некроза опухолей у больных сахарным диабетом типа 2. В кн.: Актуальные вопросы клинической эндокринологии. Ярославль, 2004. C. 34-7.
  4. Белякова Н.А., Мазурова В.И. Ожирение. СПб., 2003. 231 с.
  5. Дедов И.И., Шестакова М.В. Сахарный диабет: диагностика, лечение, профилактика. М., 2011. 808 с.
  6. Джанашия П.Х., Мирина Е.Ю. Нарушение липидного обмена при сахарном диабете 2 типа и варианты его коррекции. РМЖ. 2008; 16(11): 1156-67.
  7. Мкртумян A.M. Патофизиологический подход в лечении сахарного диабета 2 типа. Леч. врач. 2008; 3: 45-50.
  8. Клебанова Е.М. Роль гормонов жировой ткани в патогенезе инсулиновой резистентности при сахарном диабете типа 2 и пути ее коррекции. Дисс.. докт. мед. наук. М., 2008.
  9. Савельева Л.В. Современный взгляд на лечение ожирения. Качество жизни. Медицина. Сахарный диабет. 2003. C. 54-7.
  10. Терещенко И.В. Эндокринная функция жировой ткани. Проблемы лечения ожирения. Клинич. медицина. 2002; 7: 9-14.
  11. Шварц В. Жировая ткань как эндокринный орган. Проблемы эндокринологии. 2009; 55: 38-43.
  12. Bertin E., Marcus C., Ruiz J.C., et al. Leutenegger m measurement of visceral adipose tissue in the core, combined with anthropometry in obese humans. Int. J. WTO Butt Exchange Disord. 2000; 24: 263-70.
  13. Colditz G.A., Willett W.C., Rotnitzky A., et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann. Intern. Med. 1995; 122(7): 481-86.
  14. Despres J.P., Tremblay A., et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes. 1989; 38: 304-09.
  15. Dicembrini I., Pala L., Rotella C.M. From Theory to Clinical Practice in the Use of GLP-1 2011. doi: 10.1155/2011/898913
  16. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., Novials A., Rottiers R., Rutten G.E., Shaw K.M.
  17. Kappe C., Patrone C., Holst J.J., et al. Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J. Gastroenterol. 2013.
  18. Kurukulasuriya R.,Banerji M.A.,Chaicen R., et al. Selective decrease in visceral fat is associated with weight loss during metformin treatment in African Americans with type 2 diabetes. Diabetes. 1999.
  19. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: an update. Ann Intern Med. 2002; 137: 25-33.
  20. Riccio A., Del Prato S., Vigili de Kreutzenberg S., Tiengo A. Glucose and lipid metabolism in noninsulin-dependent diabetes. Effect of metformin. Diabet. Metab. 1991; 17: 180-84.
  21. Lonnqvist F., Thome A., Nilsell K., Arner P., et al. A pathogenic role of visceral fat beta 3-adrenoceptors in obesity. J. Clin. Invest. 1995; 5(3): 1109-16.
  22. Nauck M.A. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. 2011.
  23. Maida A., Lamont B.J., Cao X., et al. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-а in mice. Diabetologia. 2011; 54(2): 339-49.
  24. Ratner R.E., Maggs D., Nielsen L.L., et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2006; 8(4): 419-28.
  25. Ross R., Fortier L., Hudson R. Specific association between inner and subcutaneous fat distribution, insulin and blood sugar levels in obese women. Treatment of Diabetes. 1996; 19: 1404-11.
  26. Riccio A., Del Prato S., Vigili de Kreutzenberg S., Tiengo A. Glucose and lipid metabolism in noninsulin-dependent diabetes. Effect of metformin. Diabet. Metab. 1991; 17: 180-84.
  27. Perfetti R., Zhou J., Doyle M.E., Egan J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeo-box-1 expression and increases endocrine cell mass in the pancreas of old, glucoseintolerant rats. Endocrinology. 2000; 141: 4600-605.
  28. Diabetologie in Klinik und Praxis. Hrsg. von H. Mehnert. Stuttgart. New York,1999.
  29. Титов В.Н. Осипов С.Г. Атеросклероз. Роль эндокринного воспаления, белков острой фазы и жирных кислот. М., 2003; 279 с.
  30. Lottenberg S.A., Giannella-Neto D., Derendorf H., et al. Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int. J. Clin. Pharmacol. Ther. 1998.
  31. Anderson P.J., Chan J.C., Chan Y.L., et al. Visceral fat and cardiovascular risk factors in Chinese NIDDM patients. Diabetes Care. 1997; 20(12): 1854-58.
  32. Kvist H., Sjöström L., Tylen U. Adipose tissue volume determinations in women by computed tomography: technical considerations. Int. J. Obes. 1986; 10(1): 53-67.
  33. Fox C.S., Massaro J.M., Hoffmann U., for example K.M., Maurovich-Horvat P., Liu C.Y., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Treatment. 2007; 116: 39-48.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies